U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

SUMMIT, N.J.--(BUSINESS WIRE)-- March 05, 2019 - Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news